HK1066166A1 - Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists - Google Patents

Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists

Info

Publication number
HK1066166A1
HK1066166A1 HK04109104.0A HK04109104A HK1066166A1 HK 1066166 A1 HK1066166 A1 HK 1066166A1 HK 04109104 A HK04109104 A HK 04109104A HK 1066166 A1 HK1066166 A1 HK 1066166A1
Authority
HK
Hong Kong
Prior art keywords
sup
formula
compounds
vla
cell
Prior art date
Application number
HK04109104.0A
Other languages
English (en)
Inventor
Volkmar Wehner
Stefanie Flohr
Horst Blum
Hartmut Rutten
Hans Ulrich Stilz
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of HK1066166A1 publication Critical patent/HK1066166A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • C07D233/74Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK04109104.0A 2001-08-01 2004-11-18 Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists HK1066166A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10137595A DE10137595A1 (de) 2001-08-01 2001-08-01 Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
PCT/EP2002/008106 WO2003011288A1 (en) 2001-08-01 2002-07-20 Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists

Publications (1)

Publication Number Publication Date
HK1066166A1 true HK1066166A1 (en) 2005-03-18

Family

ID=7693930

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04109104.0A HK1066166A1 (en) 2001-08-01 2004-11-18 Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists

Country Status (30)

Country Link
US (1) US6962937B2 (ja)
EP (1) EP1414444B1 (ja)
JP (1) JP4676697B2 (ja)
KR (1) KR100910930B1 (ja)
CN (1) CN1537000B (ja)
AR (1) AR036349A1 (ja)
AT (1) ATE391504T1 (ja)
AU (1) AU2002328931B2 (ja)
BR (1) BR0211535A (ja)
CA (1) CA2455966C (ja)
CO (1) CO5550452A2 (ja)
DE (2) DE10137595A1 (ja)
DK (1) DK1414444T3 (ja)
ES (1) ES2301673T3 (ja)
HK (1) HK1066166A1 (ja)
HR (1) HRP20040108A2 (ja)
HU (1) HUP0401406A3 (ja)
IL (2) IL160093A0 (ja)
MX (1) MXPA04000041A (ja)
MY (1) MY133467A (ja)
NO (1) NO326696B1 (ja)
NZ (1) NZ530887A (ja)
PE (1) PE20030348A1 (ja)
PL (1) PL365396A1 (ja)
PT (1) PT1414444E (ja)
RS (1) RS6104A (ja)
RU (1) RU2318815C2 (ja)
TW (1) TWI325863B (ja)
WO (1) WO2003011288A1 (ja)
ZA (1) ZA200400194B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539744A4 (en) 2002-07-11 2007-06-06 Vicuron Pharm Inc N-HYDROXYAMIDE DERIVATIVES WITH ANTIBACTERIAL EFFECT
EP2093218A1 (en) * 2008-02-22 2009-08-26 Ruggero Fariello Arylalkyl substituted imidazolidinones
CA2723358A1 (en) * 2008-05-05 2009-11-12 Allison B. Reiss Method for improving cardiovascular risk profile of cox inhibitors
PL3326645T3 (pl) 2010-10-25 2020-09-21 Biogen Ma Inc. Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach sVCAM i/lub sMAdCAM

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE235866C (ja)
DE4009506A1 (de) 1990-03-24 1991-09-26 Hoechst Ag Hydantoinderivate
DE4126277A1 (de) 1991-08-08 1993-02-11 Cassella Ag Hydantoinderivate
DK0626861T4 (da) 1992-01-13 2004-08-16 Biogen Inc Behandling af astma.
DE69309906T2 (de) 1992-02-12 1997-11-06 Biogen, Inc., Cambridge, Mass. Behandlung für entzündungserkrankung des darmes
DE4207254A1 (de) 1992-03-07 1993-09-09 Cassella Ag 4-oxo-2-thioxoimidazolidin-derivate
DE4213634A1 (de) 1992-04-24 1993-10-28 Cassella Ag 2,4-Dioxo-imidazolidin-Derivate
DE4224414A1 (de) 1992-07-24 1994-01-27 Cassella Ag Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung
DE4228717A1 (de) 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
SG52262A1 (en) 1993-01-08 1998-09-28 Tanabe Seiyaku Co Peptide inhibitors of cell adhesion
CA2153692C (en) 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
EP0682529B2 (en) 1993-02-09 2005-12-28 Biogen Idec MA, Inc. Antibody for the treatment of insulin dependent diabetes
DE4308034A1 (de) 1993-03-13 1994-09-15 Cassella Ag Neue Heterocyclen, ihre Herstellung und ihre Verwendung
DE4427979A1 (de) 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
AU693143B2 (en) 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
AU703152B2 (en) 1994-01-25 1999-03-18 Biogen Ma Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
CA2193828A1 (en) 1994-06-29 1996-01-11 Timothy P. Kogan Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
DE19515177A1 (de) 1995-04-28 1996-10-31 Cassella Ag Hydantoinderivate als Zwischenprodukte für pharmazeutische Wirkstoffe
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
DK0796855T3 (da) * 1996-03-20 2002-05-27 Hoechst Ag Hæmmere af knogleresorption og vitronectin-receptorantagonister
JP2000516596A (ja) 1996-07-25 2000-12-12 バイオジェン,インコーポレイテッド 細胞接着インヒビター
DE19647381A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647380A1 (de) 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
PL323130A1 (en) 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
WO1998042656A1 (en) 1997-03-21 1998-10-01 Cytel Corporation Novel compounds
DE19741235A1 (de) * 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
SK5462000A3 (en) 1997-10-31 2001-02-12 Aventis Pharma Ltd Substituted anilides
GB9723789D0 (en) 1997-11-12 1998-01-07 Zeneca Ltd Chemical compounds
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
AU3716499A (en) 1998-04-21 1999-11-08 Aventis Pharma Limited Substituted diamines and their use as cell adhesion inhibitors
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
NZ508033A (en) 1998-06-30 2002-12-20 Pfizer Prod Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
WO2000002903A1 (en) 1998-07-10 2000-01-20 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
DE19922462A1 (de) * 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
CN1537000B (zh) 2010-05-12
NZ530887A (en) 2005-09-30
KR100910930B1 (ko) 2009-08-06
IL160093A0 (en) 2004-06-20
IL160093A (en) 2009-05-04
AR036349A1 (es) 2004-09-01
RU2318815C2 (ru) 2008-03-10
BR0211535A (pt) 2004-07-13
HRP20040108A2 (en) 2004-06-30
DE10137595A1 (de) 2003-02-13
MXPA04000041A (es) 2004-05-21
ATE391504T1 (de) 2008-04-15
NO20040426L (no) 2004-03-26
CN1537000A (zh) 2004-10-13
MY133467A (en) 2007-11-30
PE20030348A1 (es) 2003-05-14
US20030109497A1 (en) 2003-06-12
PL365396A1 (en) 2005-01-10
DK1414444T3 (da) 2008-08-04
AU2002328931B2 (en) 2008-04-24
JP4676697B2 (ja) 2011-04-27
RU2004105966A (ru) 2005-06-27
WO2003011288A1 (en) 2003-02-13
KR20040020076A (ko) 2004-03-06
PT1414444E (pt) 2008-05-27
NO326696B1 (no) 2009-02-02
DE60226032T2 (de) 2009-05-20
CO5550452A2 (es) 2005-08-31
CA2455966A1 (en) 2003-02-13
ZA200400194B (en) 2005-03-14
JP2005504033A (ja) 2005-02-10
RS6104A (en) 2006-10-27
US6962937B2 (en) 2005-11-08
DE60226032D1 (de) 2008-05-21
CA2455966C (en) 2011-09-20
TWI325863B (en) 2010-06-11
ES2301673T3 (es) 2008-07-01
EP1414444A1 (en) 2004-05-06
HUP0401406A3 (en) 2004-11-29
HUP0401406A2 (hu) 2004-10-28
EP1414444B1 (en) 2008-04-09

Similar Documents

Publication Publication Date Title
AU4037199A (en) Imidazolidine derivatives, the production thereof, their use and pharmaceutical preparations containing the same
MY118313A (en) Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
MY123865A (en) Novel heterocycles as inhibitors of leucocyte adhesion and as vla-4 antagonists
MY118176A (en) Heterocycles as inhibitors of leucocyte adhesion and as vla-4-antagonists
MY119617A (en) 5-membered ring heterocycles as inhibitors of leucocyte adhesion and as vla-4 antagonists
MY121745A (en) 2,4-substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them.
WO1995014007B1 (en) Phenyl-alkyl imidazoles as h3-receptor antagonists
MXPA03009439A (es) Derivados de 4,5-dihidro-1h-pirazol que tienen una potente actividad antagonistica de cb1.
AU2337097A (en) Meta-substituted phenylene derivatives and their use as alphavbeta3 integrin antagonists or inhibitors
YU14196A (sh) Estri i amidi di-supstituisanog 1,4-piperidina, postupci za njihovo dobijanje i farmakološke kompozicije koje ih sadrže
US20190322633A1 (en) Stromal derived factor inhibition and cxcr4 blockade
MY134191A (en) Novel 5-membered ring heterocycles, their preparation their use and pharmaceutical preparations comprising them
WO2004060376A8 (en) The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
HK1066166A1 (en) Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists
ATE267803T1 (de) Carbonsäureamide, deren herstellung und deren verwendung als arzneimittel
TR200103856T2 (tr) Naftiridin türevleri, bunların preparasyon işlemleri, kullanımları ve farmasötik kompozisyonlar.
YU70803A (sh) Derivati imidazolidina, njihovo dobijanje i njihova upotreba kao antiinflamatornih agensa
TWI256386B (en) Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
Rosenthal et al. Comparative effects on the immune system of methotrexate and trimetrexate
SG146692A1 (en) Melanin concentrating hormone antagonists
WO2001070695A8 (en) Pyridine derivatives as inhibitors of p38
TH64558A (ja)

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150720